Cargando…

Comparison of potency assays to assess SARS-CoV-2 neutralizing antibody capacity in COVID-19 convalescent plasma

Convalescent plasma is plasma collected from individuals after resolution of an infection and the development of antibodies. Passive antibody administration by transfusion of convalescent plasma is currently in clinical evaluations to treat COVID-19 patients. The level of neutralizing antibodies var...

Descripción completa

Detalles Bibliográficos
Autores principales:	von Rhein, Christine, Scholz, Tatjana, Henss, Lisa, Kronstein-Wiedemann, Romy, Schwarz, Tatjana, Rodionov, Roman N., Corman, Victor M., Tonn, Torsten, Schnierle, Barbara S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7707675/ https://www.ncbi.nlm.nih.gov/pubmed/33275926 http://dx.doi.org/10.1016/j.jviromet.2020.114031

Ejemplares similares

Stability and neutralising capacity of SARS-CoV-2-specific antibodies in convalescent plasma
por: Tonn, Torsten, et al.
Publicado: (2020)

Silvestrol Inhibits Chikungunya Virus Replication
por: Henss, Lisa, et al.
Publicado: (2018)

Potential benefit of convalescent plasma transfusions in immunocompromised patients with COVID-19
por: Rodionov, Roman N, et al.
Publicado: (2021)

Improved Human Erythropoiesis and Platelet Formation in Humanized NSGW41 Mice
por: Rahmig, Susann, et al.
Publicado: (2016)

Novel evidence that the ABO blood group shapes erythropoiesis and results in higher hematocrit for blood group B carriers
por: Kronstein-Wiedemann, Romy, et al.
Publicado: (2023)

Donors for SARS-CoV-2 Convalescent Plasma for a Controlled Clinical Trial: Donor Characteristics, Content and Time Course of SARS-CoV-2 Neutralizing Antibodies
por: Körper, Sixten, et al.
Publicado: (2021)

K562 erythroleukemia line as a possible reticulocyte source to culture Plasmodium vivax and its surrogates
por: Kronstein-Wiedemann, Romy, et al.
Publicado: (2020)

Longitudinal Analysis of Coronavirus-Neutralizing Activity in COVID-19 Patients
por: Hastert, Florian D., et al.
Publicado: (2022)

SARS-CoV-2-specicific humoral immunity in convalescent patients with mild COVID-19 is supported by CD4(+) T-cell help and negatively correlated with Alphacoronavirus-specific antibody titer
por: Odendahl, Marcus, et al.
Publicado: (2022)

EV-3, an endogenous human erythropoietin isoform with distinct functional relevance
por: Bonnas, Christel, et al.
Publicado: (2017)

Identification of Functional Determinants in the Chikungunya Virus E2 Protein
por: Weber, Christopher, et al.
Publicado: (2017)

Establishment of an Alphavirus-Specific Neutralization Assay to Distinguish Infections with Different Members of the Semliki Forest Complex
por: Henss, Lisa, et al.
Publicado: (2019)

SARS-CoV-2 Infects Red Blood Cell Progenitors and Dysregulates Hemoglobin and Iron Metabolism
por: Kronstein-Wiedemann, Romy, et al.
Publicado: (2022)

The green tea catechin epigallocatechin gallate inhibits SARS-CoV-2 infection
por: Henss, Lisa, et al.
Publicado: (2021)

Reactive T Cells in Convalescent COVID-19 Patients With Negative SARS-CoV-2 Antibody Serology
por: Steiner, Sophie, et al.
Publicado: (2021)

Development of a Sensitive Detection Method for Alphaviruses and Its Use as a Virus Neutralization Assay
por: Schmidt, Christin, et al.
Publicado: (2021)

A neutralization assay for chikungunya virus infections in a multiplex format
por: Weber, Christopher, et al.
Publicado: (2014)

Development of an in Vitro Potency Assay for Anti-anthrax Lethal Toxin Neutralizing Antibodies
por: Whiting, Gail, et al.
Publicado: (2012)

Neutralizing antibodies in convalescent patients
por: Uhl, Lion F. K., et al.
Publicado: (2020)

Suramin is a potent inhibitor of Chikungunya and Ebola virus cell entry
por: Henß, Lisa, et al.
Publicado: (2016)

Hematopoietic Stem/Progenitor Cells and Engineering: SARS-COV-2 INFECTS RED BLOOD CELL PROGENITORS AND DYSREGULATES HEMOGLOBIN AND IRON METABOLISM
por: Kronstein-Wiedemann, R., et al.
Publicado: (2023)

High-capacity assay to quantify the clonal heterogeneity in potency of mesenchymal stem cells
por: O’Connor, Kim C, et al.
Publicado: (2011)

Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants
por: Moriyama, Saya, et al.
Publicado: (2021)

Impact of pathogen-reduction technologies on COVID-19 convalescent plasma potency
por: Focosi, D., et al.
Publicado: (2021)

Assaying the Potency of Influenza Vaccines
por: Minor, Philip D.
Publicado: (2015)

SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against Omicron subvariants BA.1, BA.2 and BA.5 and can be predicted by anti-S antibody concentrations in serological assays
por: Seidel, Alina, et al.
Publicado: (2023)

Evaluation of Potency on Diphtheria and Tetanus Toxoid for Adult Vaccines by In Vivo Toxin Neutralization Assay Using National Reference Standards
por: Choi, Chan Woong, et al.
Publicado: (2018)

Bananas decrease acetaminophen potency in in vitro assays
por: Uesawa, Yoshihiro, et al.
Publicado: (2018)

SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons
por: Rössler, Annika, et al.
Publicado: (2022)

Equal Neutralization Potency of Antibodies Raised against Abrin Subunits
por: Gal, Yoav, et al.
Publicado: (2020)

Temporal Analysis of Serial Donations Reveals Decrease in Neutralizing Capacity and Justifies Revised Qualifying Criteria for Coronavirus Disease 2019 Convalescent Plasma
por: Girardin, Roxie C, et al.
Publicado: (2021)

Comparing SARS-CoV-2 neutralizing antibody levels in convalescent unvaccinated, convalescent vaccinated, and naive vaccinated subjects
por: Dulipsingh, Latha, et al.
Publicado: (2023)

Evaluation of SARS‐CoV‐2 antibody titers and potency for convalescent plasma donation: a brief commentary
por: Wouters, Elise, et al.
Publicado: (2020)

Neutralization of SARS-CoV-2 variants by convalescent and vaccinated serum
por: Bates, Timothy A., et al.
Publicado: (2021)

ADCC potency assay: increased standardization with modified lymphocytes
por: Bretaudeau, Laurent, et al.
Publicado: (2011)

Optimizing an immunomodulatory potency assay for Mesenchymal Stromal Cell
por: Hansen, Stine Bangsgaard, et al.
Publicado: (2022)

GM-CSF in murine psoriasiform dermatitis: Redundant and pathogenic roles uncovered by antibody-induced neutralization and genetic deficiency
por: Scholz, Tatjana, et al.
Publicado: (2017)

Unravelling Anti-Melanogenic Potency of Edible Mushrooms Laetiporus sulphureus and Agaricus silvaticus In Vivo Using the Zebrafish Model
por: Pavic, Aleksandar, et al.
Publicado: (2021)

Surrogate potency assays: Comparison of binding profiles complements dose response curves for unambiguous assessment of relative potencies
por: Karlsson, Robert, et al.
Publicado: (2018)

Early administration of COVID‐19 convalescent plasma with high titer antibody content by live viral neutralization assay is associated with modest clinical efficacy
por: Belov, Artur, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_h7uhsnuedqeuogsvvifnc63m4r